Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $1.58

Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $1.58, but opened at $1.65. Adaptimmune Therapeutics shares last traded at $1.65, with a volume of 131,882 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Adaptimmune Therapeutics in a research report on Friday, December 29th. They set a "hold" rating for the company.

Adaptimmune Therapeutics Stock Performance

The company has a 50-day moving average price of $1.28 and a two-hundred day moving average price of $0.86. The stock has a market capitalization of $1.57 billion, a P/E ratio of -2.87 and a beta of 2.40.

Institutional Trading of Adaptimmune Therapeutics

Large investors have recently made changes to their positions in the company. Barclays PLC acquired a new stake in shares of Adaptimmune Therapeutics in the 2nd quarter valued at about $46,000. Black Maple Capital Management LP acquired a new stake in shares of Adaptimmune Therapeutics in the 2nd quarter valued at about $65,000. Marquette Asset Management LLC acquired a new position in Adaptimmune Therapeutics during the 3rd quarter valued at about $77,000. Harbor Capital Advisors Inc. boosted its stake in Adaptimmune Therapeutics by 9.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company's stock valued at $117,000 after purchasing an additional 13,317 shares during the last quarter. Finally, Key Client Fiduciary Advisors LLC boosted its stake in Adaptimmune Therapeutics by 6.4% during the 4th quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company's stock valued at $267,000 after purchasing an additional 20,295 shares during the last quarter. 31.37% of the stock is currently owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.